The 20 Best Pancreatic Cancer Doctors Near Me in Ann Arbor, MI

Dr. Zalupski is an Professor of Medicine in the division of Medical Oncology at the UMMC. He completed medical school, an internal medicine residency and a medical oncology fellowship at Wayne State University in Detroit. Dr. Zalupski's clinical and research interest is in experimental therapeutics of gastrointestinal malignancies and sarcomas. He also serves as the medical director of the Multidisciplinary Pancreatic Cancer Clinic. Dr. Zalupski is rated as an Elite provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Pancreaticoduodenectomy. Dr. Zalupski is board certified in Internal Medicine and Medical Oncology.

Dr. Bednar is a faculty member in the Department of Surgery at the University of Michigan.His undergraduate training was done at Princeton University, where he graduated with a Bachelor of Arts degree in molecular biology in 2000. After that he transitioned to the Lewis Katz School of Medicine of Temple University in Philadelphia. Dr. Bednar spent seven years in the combined MD/PhD program where he earned an MD and PhD in Microbiology and Immunology in the laboratory of Dr. Thomas Rogers. His dissertation thesis focused on how human monocytes respond to the complex external environment present during an infection or inflammatory state. After the completion of his medical training he was accepted to the General Surgery Residency program at the University of Michigan. During his time in Ann Arbor, he also spent two years in a postdoctoral research fellowship in the laboratories of Dr. Diane Simeone and Dr. Marina Pasca di Magliano. During Dr. Bednar's research time, he studied the basic biology of pancreatic cancer, which led to his evolving interest in cancer patient care. He finished his clinical training in the Complex General Surgical Oncology Fellowship program at the University of Pittsburgh and was recruited back to the University of Michigan to become a part of the pancreatic cancer research group that has developed here in the past decade. Dr. Bednar is a board-certified general surgeon and currently undergoing board certification for additional specialization of Complex General Surgical Oncology. He is also BLS/ACLS certified.Dr. Bednar's clinical and research effort up to now has been recognized through several awards. He received the Dr. Herman Brown Award for Excellence in the Study of the Art and Science of Surgery from the Department of Surgery, Lewis Katz School of Medicine, Temple University as a recognition for his care of the surgical patients and his research work while he was a medical student. Dr. Bednar's work on pancreatic cancer was recognized and supported by an American College of Surgeons Research Fellowship. He also received the Robert V. Danto Cancer Research Award from the Michigan chapter of the American College of Surgeons for his postdoctoral research work. His work was chosen to be presented at the Owen Wangensteen Surgical Forum during the annual American College of Surgeons meeting in 2013 and received the Best Oral Presentation award at the 24th Annual Moses Gunn Research Conference of the Department of Surgery at the University of Michigan in 2012.Clinical Specialization:Dr. Bednar is a practicing general and oncologic surgeon. His practice encompasses the full gamut of general surgery and complex abdominal and soft tissue surgical oncology. During his fellowship training, he also received specific instruction on the DaVinci robotic surgery platform and hope to continue to support the already-established efforts in this arena. Dr. Bednar is rated as an Elite provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bednar is board certified in Surgery and Complex General Surgical Oncology.

Dr. Clifford S. Cho is the C. Gardner Child Professor of Surgery in the Division of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery at Michigan Medicine.Dr. Cho is an Honors graduate of Brown University and AOA graduate of the Vanderbilt University School of Medicine. He completed his general surgery residency and transplantation immunology postdoctoral research fellowship at the University of Wisconsin, where he served as Chief Administrative Resident. He completed his surgical oncology fellowship at the Memorial Sloan-Kettering Cancer Center, where he served as Chief Administrative Fellow. He joined the faculty of the University of Wisconsin School of Medicine and Public Health in 2006, where he was promoted to Associate Professor with Tenure and named the Ronald and Patricia Kissinger Professor of Surgical Oncology. He served as Chief of the Division of Surgical Oncology, Associate Residency Program Director, and co-Director of the Gastrointestinal Disease Oriented Team in the University of Wisconsin Carbone Cancer Center before moving to the University of Michigan in 2016.Dr. Cho’s academic focus is on hepatopancreatobiliary and gastrointestinal malignancies, cancer immunology, and the mentorship of clinical and research trainees. He has lectured on these academic interests in over 15 national and international visiting professorships, and was named the James IV Traveler in 2014. He has published over 120 peer-reviewed manuscripts and book chapters and currently serves on the editorial boards of Surgery and the Journal of Gastrointestinal Surgery. He is the Principal Investigator of a VA Merit Review-funded cancer immunology laboratory that is working to understand cancer-induced T cell suppression, and to identify novel T cell-based strategies for cancer immunotherapy. His laboratory has been continuously funded since 2006 by extramural support from the Veteran’s Administration, National Institutes of Health, American College of Surgeons, and Central Surgical Association, and is a member of the VA Oncology Merit Review study section. He has held a number of national academic leadership positions and is a member of over 15 surgical societies, including the American Surgical Association, Society of Clinical Surgery, Society of University Surgeons, and Surgical Biology Club II. Dr. Cho is rated as an Elite provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Cho is board certified in Surgery.

Dr. Sahai is the Leader of the Gastrointestinal Medical Oncology Section and Associate Professor in the Division of Hematology-Oncology, Department of Internal Medicine. Dr. Sahai is also a member of the University of Michigan Rogel Cancer Center and Director of Tumor Response Assessment Core.Dr. Sahai attended medical school at the Government Medical College at Amritsar with the Baba Farid University of Health Science in India. He then completed his Masters in Clinical Epidemiology at Harvard School of Public Health followed by Internal Medicine residency training at University of Pittsburgh where he met his wife. He completed his fellowship in Hematology-Oncology at Northwestern University where he also served as the Chief Fellow. Subsequently, Dr. Sahai joined University of Michigan as Assistant Professor in Internal Medicine in 2013.Dr. Sahai is a clinician-scientist who sees patients within the Multidisciplinary Pancreatic and Liver Tumor programs. As a clinical investigator he is the Principal Investigator on several investigator-initiated clinical trials open across the U.S. His translational research program leverages the pancreaticobiliary cancer biobanks that he directs for the therapeutic investigation of novel compounds in patient-derived cell lines and xenograft models to help develop novel phase 1/2 investigator-initiated clinical trials. Dr. Sahai is rated as an Elite provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor.

Dr. Timothy L. Frankel is a faculty member within the Section of General Surgery at the University of Michigan. He graduated Magna Cum Laude from Connecticut College in 2000 with a B.A. in Physics and was elected into Phi Beta Kappa. He earned his medical degree from George Washington University in 2004 and was inducted into the Alpha Omega Alpha Honor Medical Society. He completed a residency in General Surgery at the University of Michigan in 2011 during which time he spent two years at the National Cancer Institute studying tumor immunology and genetic engineering. He developed techniques to genetically modify peripheral blood lymphocytes allowing them to more effectively target tumors for destruction. His work resulted in multiple publications and awards including the James Crudup Surgical Research Award. After completion of residency, he completed a two-year surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Clinical Specialization:His clinical interests are in the treatment of gastrointestinal malignancies including cancers of the liver, pancreas and stomach. He has published multiple clinical papers on techniques in liver resection for colorectal metastases. Dr. Frankel is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Frankel is board certified in Surgery and Complex General Surgical Oncology.

Dr. Kwon joined the Division of Gastroenterology in 2005 and is currently a Clinical Professor. He received his bachelor's degree from Amherst College and his medical degree from UCLA Medical School. He completed his internal medicine residency at Cedars-Sinai Medical Center and his gastroenterology fellowship at Brigham and Women's Hospital (BWH). He also completed his advanced endoscopy fellowship at the combined BWH and Massachusetts General Hospital program. He earned his Master of Science in Clinical Research Design and Statistical Analysis at the University of Michigan. Dr. Kwon is currently the Director of Advanced Endoscopy, Program Director for the Advanced Endoscopy fellowship, and Co-director of the Comprehensive Pancreas Program. He also serves as the Medical Director of the Michigan Chapter of the National Pancreas Foundation. He is a principal investigator in several independently funded research studies and has been an author on over 100 publications, including multiple research studies, national guidelines, and book chapters. He is a sought-after speaker, having served as invited faculty at multiple regional, national and international courses. Dr. Kwon is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Bile Duct Obstruction, Pancreatic Cancer, Endoscopy, and Lithotripsy. Dr. Kwon is board certified in Gastroenterology.

Dr. Hari Nathan is a board-certified complex general surgical oncologist and Associate Professor of Surgery with Tenure. Dr. Nathan completed both his undergraduate and medical education with honors at The Johns Hopkins University. He also completed advanced training in health services research and was awarded a PhD from The Johns Hopkins Bloomberg School of Public Health. Dr. Nathan completed his clinical residency training in general surgery at The Johns Hopkins Hospital. He subsequently completed a clinical fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center, where he also served as the Chief Administrative Fellow in Surgery. He joined the faculty of the University of Michigan in 2014. Clinical Specialization: Dr. Nathan's clinical focus includes the multi-disciplinary treatment of tumors of the pancreas, liver, bile duct, and stomach. He has particular interests in the treatment of liver metastases from colorectal cancer and directs Michigan Medicine’s Hepatic Artery Infusion Pump (HAIP) Program. He also serves as the Surgical Director of the Multidisciplinary Pancreatic Cancer Clinic, coordinating the efforts of a multidisciplinary team at the busiest pancreatic cancer program in Michigan. Dr. Nathan is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Nathan is board certified in Surgery and Complex General Surgical Oncology.

Thomas Enzler, MD PhD, is an Assistant Professor in the Division of Hematology and Oncology. He received his Master of Science from ETH Zurich and his Medical Degree from University of Basel, Switzerland. After completion of residency in Internal Medicine at University Hospitals of Zurich and Basel, Dr. Enzler did a research fellowship at the Dana Farber Cancer Institute, Harvard Medical School, Boston. There, he worked on projects focusing on tumor immune surveillance and his work resulted in several publications and in a PhD ‘magna cum laude’ in Biochemistry/Immunology (Harvard Medical School Boston/Max Delbrueck Center Berlin). He then moved to University of California San Diego to study signaling pathways of cancer cells and immune cells. While there, he successfully obtained ECFMG certification prior to doing clinic and laboratory research at Stanford University. From California Dr. Enzler went to Germany to do a Hematology and Oncology fellowship at University of Goettingen and he received board certification in both in Germany and in Switzerland. Dr. Enzler decided to return to the U.S. and completed U.S. residency in Internal Medicine at University of Arizona in Tucson. Following U.S. residency training, Dr. Enzler completed fellowship in Hematology and Oncology at Columbia University Medical Center, New York, where he worked on several research projects on gastrointestinal cancers. Dr. Enzler is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. Dr. Enzler is board certified in Internal Medicine, Medical Oncology, and Hematology.

Dr. Cuneo grew up in Northern California. He studied Biological and Environmental Engineering at Cornell University in Ithaca, NY. Dr. Cuneo received his Doctor of Medicine degree from Vanderbilt University School of Medicine in 2007 and completed an internship there in 2008. In 2008 he started his residency in Radiation Oncology at Duke University Medical Center. Dr. Cuneo has been an Assistant Professor in the Department of Radiation Oncology at the University of Michigan since 2012. Dr. Cuneo is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Liposarcoma, Liver Cancer, and Pancreaticoduodenectomy. Dr. Cuneo is board certified in Radiation Oncology.

Dr. Lawrence structured his career to prepare to be a physician scientist by obtaining both an MD and PhD. He initially pursued internal medicine and medical oncology, but ultimately settled on radiation oncology. He is board certified in all 3 areas. He has had an active clinical practice in radiation oncology for 30 years specializing in the treatment of patients with gastrointestinal malignancies and CNS tumors.Dr. Lawrence has focused his research career in two main areas. First, in collaboration with basic scientists he developed a laboratory program in chemotherapeutic radiation sensitizers and, more recently, has studied how to integrate molecularly targeted therapies. He collaborates with basic science faculty interested in translational research to investigate new combinations that can form the basis for rational clinical trials. The second area of focus involves the use of highly conformal radiation therapy in the treatment of brain and gastrointestinal cancers. In particular, he is focusing, in collaboration with medical physicists, radiologists, imaging scientists, and biologists, on the concept of adapting treatment to the individual patient response, assessed both by state-of-the-art imaging and plasma biomarkers.Dr. Lawrence is the author of over 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 20 years. Dr. Lawrence is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Lawrence is board certified in Radiation Oncology, Medical Oncology, and Internal Medicine.

Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology.

Eileen received her undergraduate chemical engineering degree from the Cooper Union and her combined MD/PhD from SUNY Stony Brook University through the Medical Scientist Training Program. She then joined the University of Michigan and completed her internal medicine residency and gastroenterology fellowship through their fast-track research pathway. She recently joined faculty at the University of Michigan and has an appointment at the University of Michigan affiliate, VA Ann Arbor Healthcare System. Her clinical practice is focused on treating patients with benign and malignant diseases of the pancreas. In her free time, she enjoys taking care of her three kids, playing the piano, volunteering at church, /and serving on the local little league board. Dr. Carpenter is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Chronic Pancreatitis, Childhood Pancreatitis, and Acute Pancreatitis. Dr. Carpenter is board certified in Internal Medicine and Gastroenterology.

Erik-Jan Wamsteker, MD is a Clinical Associate Professor in the Division of Gastroenterology and Hepatology. Dr. Wamsteker earned his medical degree from UMDNJ Rutgers Medical school (New Jersey Medical School). He completed his internal medicine residency at the University of Michigan and Gastroenterology Fellowship where he focused his training in Advanced Endoscopy with a focus in ERCP and EUS. He is board certified in Gastroenterology.Dr. Wamsteker has authored numerous peer-reviewed articles, abstracts, and book chapters. He has served as a councilor of the AGA Institute Council Pancreatic Disorders Section as well as a counselor to the ACG practice parameters committee tasked with clinical guideline development and serves on the Board of the National Pancreas Foundations Michigan Chapter. He is an active faculty member in the training of GI fellows both for the general GI fellowship as well as Advanced Endoscopy Fellowship programs. He runs the monthly Advanced Endoscopy Conference as well as gives didactic lectures to Internal Medicine residents and GI fellows on various topics focused on endoscopic management of pancreatic and biliary disorders as well as endoscopic oncology.Personal Interests:Music history, listening to music especially on vinyl, print making, greyhounds. Dr. Wamsteker is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Neuroma Biliary Tract, Bile Duct Obstruction, Childhood Pancreatitis, Pancreatectomy, and Gastrectomy. Dr. Wamsteker is board certified in Gastroenterology.

Allison Schulman, MD, MPH, FASGE, FACG is an Associate Professor and dually appointed in the Division of Gastroenterology and Hepatology and the Department of Surgery. She received her bachelor's degree from Cornell University in Ithaca, New York, and her medical degree from Weill Cornell Medical College in New York City, where she was inducted into the Alpha Omega Alpha (AOA) Medical Honor Society. She received a Master’s in Public Health (MPH) at Harvard University. She completed her residency in Internal Medicine at the Brigham and Women's Hospital in Boston, MA. Following residency training, Dr. Schulman completed fellowship in Gastroenterology, and went on to complete two additional fellowships in Bariatric Endoscopy followed by Advanced/Therapeutic Endoscopy. All of her training was at Harvard/Brigham and Women's Hospital. She joined faculty at Michigan in 2017 and was appointed Director of Bariatric Endoscopy and more recently selected as Chief of Endoscopy in 2023.Dr. Schulman's research has focused on endoscopic management of obesity and device development/innovation in therapeutic endoscopy. She is specifically interested in the management of complications following bariatric surgery, primary endoscopic therapy for obesity, and therapeutic endoscopic ultrasound (EUS). She also has interests in interventional hepatology and ERCP.She is a member of the Clinical Excellence Society and participates in committees through many gastroenterology and surgical societies, and is the current Chair of the Association of Bariatric Endoscopy (ABE/ASGE). Dr. Schulman is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Gastrointestinal Fistula, Choledocholithiasis, Hereditary Pancreatitis, Gastric Bypass, and Endoscopy. Dr. Schulman is board certified in Gastroenterology.

Xhorlina Marko is a Radiologist and an Interventional Radiologist practicing medicine in Ann Arbor, Michigan. Dr. Marko is rated as an Experienced provider by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Deep Vein Thrombosis, SVC Obstruction, Nasal Flaring, Thrombectomy, and Bone Marrow Aspiration. Dr. Marko is board certified in Interventional Radiology & Diagnostic Radiology.

Jessica Fried is a Radiologist and an Interventional Radiologist practicing medicine in Ann Arbor, Michigan. Dr. Fried is rated as an Experienced provider by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Visceromegaly, Alcoholic Cirrhosis, Cholangiocarcinoma (Bile Duct Cancer), and Cirrhosis. Dr. Fried is board certified in Diagnostic Radiology.

Nikita Consul is a Radiologist practicing medicine in Ann Arbor, Michigan. Dr. Consul is rated as an Experienced provider by MediFind in the treatment of Pancreatic Cancer. Her clinical expertise encompasses Giant Mammary Hamartoma, Liver Cancer, Bannayan-Riley-Ruvalcaba Syndrome, and Lhermitte-Duclos Disease. Dr. Consul is board certified in Diagnostic Radiology.

Krishnavel Chathadi is a Gastroenterologist practicing medicine in Ypsilanti, Michigan. Dr. Chathadi is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Bile Duct Obstruction, Bile Duct Stricture, Endoscopy, and Colonoscopy.

Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023. Dr. Chang is rated as an Advanced provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Chang is board certified in Radiation Oncology.

Evan Glazer, MD, PhD, FACS, is the Clinical Director of the Pancreatic Cancer Program at Michigan Medicine and the Associate Director of Clinical Research in the Rogel and Blondy Center for Pancreatic Cancer. Dr. Glazer earned his medical degree and a master's degree in public health at the George Washington University in Washington, DC. Subsequently, he completed residency in general surgery and completed a PhD in Cancer Biology at the University of Arizona, in Tucson, AZ. Dr. Glazer completed an NIH funded T32 training fellowship at the M.D. Anderson Cancer Center in Houston, TX. He completed a fellowship in complex general surgical oncology at the H. Lee Moffitt Cancer Center in Tampa, FL. Dr. Glazer is board certified in complex general surgical oncology and general surgery. His clinical and research focuses are on pancreatic and liver malignancies.After completing fellowship in Tampa, Dr. Glazer joined the University of Tennessee Health Science Center in Memphis, TN, and rose in rank to Associate Professor. He served as program director of the complex general surgical oncology fellowship there as well as associate program director for research in the general surgery residency program. Dr. Glazer is a member of the American College of Surgeons, American Association for Cancer Research, Society of Surgical Oncology, Association of Academic Surgery, and American Society of Clinical Oncology. With a national reputation, he has served on the Hepatobiliary Panel and Pancreatic Adenocarcinoma Panel for the National Comprehensive Cancer Network. He has served numerous roles for the Society of Surgical Oncology. Dr. Glazer is rated as an Advanced provider by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Liver Cancer, Fibrolamellar Carcinoma, Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Glazer is board certified in Surgery and Complex General Surgical Oncology.